ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2022

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.

Magnus Johnsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.